Erschienen in:
05.08.2022 | ASO Author Reflections
ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?
verfasst von:
Mikail Gögenur, MD, Claus Lindbjerg Andersen, PhD, Ismail Gögenur, DMSc
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2022
Einloggen, um Zugang zu erhalten
Excerpt
Neoadjuvant treatment has been adopted in the treatment of several cancers to downsize tumors and treat micrometastic disease to reduce local and distant recurrence.
1 Circulating tumor DNA (ctDNA) has been established as an accurate measure of minimal residual disease in patients undergoing surgery,
2,3 while its role in the neoadjuvant setting remains to be elucidated. …